AI Article Synopsis

  • The study focused on creating stable oral liquid formulations of idebenone for infants using different vehicles like Ora-Plus, Ora-Sweet, and Inorpha.
  • Idebenone remained stable for 90 days specifically in the Inorpha formulation at both 5°C and 25°C, while other formulations showed reduced stability (14 to 20 days).
  • pH levels changed minimally in the Ora-Plus and Ora-Sweet combinations, with no significant changes in color, odor, or bacterial growth noted during storage.

Article Abstract

Adapted forms for administration to infants are limited. The proposed study was performed to propose oral liquid formulations of idebenone in Ora-Plus and either Ora-Sweet or Ora-Sweet SF, Ora-Blend, Ora-Blend SF and Inorpha. Each formulation was stored in 30 ml amber glass bottle at 5 or 25 °C for 90 days. Idebenone contents in these suspensions, determined by a stability-indicating high-performance liquid chromatography method, remained stable at least 90 days in Inorpha when stored at the two temperatures. In Ora-Blend, the stability was estimated at 14 days and in other suspensions at 20 days at the two temperatures. After 90 days storage, the pH of Ora-Plus and Ora-Sweet or Ora-Sweet SF changed between -0.10 and -0.25 units. For others suspensions, the pH changes were not significant (< -0.09 unit). No change was observed in color, odor or visual microbiology. To conclude, we recommended the use of idebenone in Inorpha vehicle stable for at least 90 days at 25 °C.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10837450.2016.1231811DOI Listing

Publication Analysis

Top Keywords

ora-plus ora-sweet
8
ora-sweet ora-sweet
8
stability study
4
study oral
4
oral pediatric
4
pediatric idebenone
4
suspensions
4
idebenone suspensions
4
suspensions adapted
4
adapted forms
4

Similar Publications

Olmesartan medoxomil (OLM) is only available in the United States as tablets. The United States Pharmacopoeia (USP) has placed OLM on its priority list of preparations that require stability data to support practitioner compounding. The purpose of the study was to develop a stability-indicating assay and then determine the beyond-use date (BUD) for an extemporaneous OLM suspension.

View Article and Find Full Text PDF

Thioguanine (TG) is available only in the form of 40 mg tablets in the United States, and the patient population in which TG is used comprises mostly children. Recognizing its importance as a therapeutic agent and limited stability data for its compounded preparation, the United States Pharmacopoeia has listed TG in its priority list of compounded preparations monographs. The goal of the present study was to generate stability data and establish a beyond-use date for compounded TG suspension.

View Article and Find Full Text PDF

Objectives: In children, supraventricular tachycardia is the most common form of arrhythmia, and propafenone is an effective class Ic antiarrhythmic agent used in this population. No suitable paediatric-specific, dosing-flexible preparation is available in Taiwan. The objective of this study was to develop a formulation of propafenone oral suspension prepared from commercially available propafenone tablets and commercially available oral syrup vehicles for related patients.

View Article and Find Full Text PDF

Eslicarbazepine acetate is an anticonvulsant drug with a recent U.S. Food and Drug Administration approval for expanded use in children and adolescents.

View Article and Find Full Text PDF

Stability of extemporaneously prepared cinacalcet oral suspensions.

Am J Health Syst Pharm

May 2018

Department of Pharmaceutical Sciences, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY

Purpose: The stability of extemporaneously prepared cinacalcet suspensions over 90 days was evaluated.

Methods: Cinacalcet 5-mg/mL suspension was prepared by triturating 30-mg cinacalcet tablets. Twelve 30-mL batches were prepared with a 1:1 mixture of Ora-Plus and either Ora-Sweet or Ora-Sweet SF (sugar free).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!